These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30897317)

  • 1. [Management of hypertriglyceridaemia].
    Scheen AJ; Wallemacq C; De Flines J; Paquot N
    Rev Med Liege; 2019 Mar; 74(3):167-172. PubMed ID: 30897317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM; Croom KF
    Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination lipid therapy in type 2 diabetes.
    Perkins WJ
    N Engl J Med; 2010 Aug; 363(7):694; author reply 694-5. PubMed ID: 20842773
    [No Abstract]   [Full Text] [Related]  

  • 6. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010 Sep; 65(9):533-9. PubMed ID: 21086587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
    Cabello I; Servitje O; Corbella X; Bardés I; Pintó X
    Clin Exp Dermatol; 2017 Apr; 42(3):276-281. PubMed ID: 28233333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation and management of hypertriglyceridaemia.
    Ferns G; Keti V; Griffin B
    J Clin Pathol; 2008 Nov; 61(11):1174-83. PubMed ID: 18955574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demystifying the management of hypertriglyceridaemia.
    Watts GF; Ooi EM; Chan DC
    Nat Rev Cardiol; 2013 Nov; 10(11):648-61. PubMed ID: 24060958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An acute edematous pancreatitis case developed on the basis of hypertriglyceridemia.
    Aslan T; Erden A; Karagoz H; Karahan S; Aykas F; Uslu E; Mutlu H; Karaman A
    Med Arch; 2013; 67(4):295-6. PubMed ID: 24520759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination lipid therapy in type 2 diabetes.
    Saely CH; Rein P; Drexel H
    N Engl J Med; 2010 Aug; 363(7):692; author reply 694-5. PubMed ID: 20701533
    [No Abstract]   [Full Text] [Related]  

  • 17. Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial.
    Wan Q; Wang F; Wang F; Guan Q; Liu Y; Wang C; Feng L; Gao G; Gao L; Zhao J
    Diabet Med; 2010 Nov; 27(11):1312-7. PubMed ID: 20968112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.
    Watts GF; Karpe F
    Heart; 2011 Mar; 97(5):350-6. PubMed ID: 21296781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.